Ardevora Asset Management LLP Has $11.12 Million Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Ardevora Asset Management LLP reduced its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 41.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,860 shares of the company's stock after selling 104,173 shares during the quarter. Ardevora Asset Management LLP owned about 0.11% of Henry Schein worth $11,119,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of HSIC. Morgan Stanley increased its position in shares of Henry Schein by 143.4% during the fourth quarter. Morgan Stanley now owns 2,337,890 shares of the company's stock valued at $186,727,000 after buying an additional 1,377,207 shares during the period. Norges Bank bought a new stake in shares of Henry Schein in the 4th quarter worth about $109,932,000. Lazard Asset Management LLC increased its stake in Henry Schein by 1,303.3% in the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company's stock worth $92,614,000 after buying an additional 1,158,451 shares during the period. Boston Partners increased its stake in Henry Schein by 4,975.9% in the 3rd quarter. Boston Partners now owns 1,080,598 shares of the company's stock worth $80,229,000 after buying an additional 1,059,309 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in Henry Schein during the 2nd quarter valued at about $36,288,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Up 1.3 %

Henry Schein stock traded up $0.89 during mid-day trading on Friday, hitting $70.86. The company's stock had a trading volume of 768,627 shares, compared to its average volume of 957,077. Henry Schein, Inc. has a 52-week low of $60.01 and a 52-week high of $85.39. The firm's 50 day moving average is $74.37 and its 200 day moving average is $72.45. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00. The company has a market cap of $9.10 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. During the same period in the previous year, the business posted $1.21 EPS. Henry Schein's revenue for the quarter was down 10.5% compared to the same quarter last year. On average, analysts anticipate that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on HSIC. Barrington Research lifted their target price on shares of Henry Schein from $82.00 to $90.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $82.00 to $88.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. SVB Leerink started coverage on shares of Henry Schein in a report on Monday, February 26th. They set a "market perform" rating and a $78.00 target price for the company. Piper Sandler boosted their price target on shares of Henry Schein from $78.00 to $86.00 and gave the company an "overweight" rating in a research report on Monday, February 26th. Finally, Evercore ISI upped their target price on shares of Henry Schein from $79.00 to $83.00 and gave the company an "in-line" rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $81.09.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now owns 209,562 shares in the company, valued at $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now owns 209,562 shares of the company's stock, valued at approximately $15,585,125.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the firm's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company's stock, valued at $5,430,462.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.